Buzzing Politics
  • News
  • Privacy Policy
  • Terms of Use
  • Disclaimer
Select Page

Senate’s Draft Bill Gives XRP, SOL, DOGE, Bitcoin-Like Status—Here’s Why It Matters

by Parshwa Turakhiya | Jan 13, 2026 | General

The Senate Banking Committee released a draft bill Tuesday that would treat XRP (CRYPTO: XRP), Solana (CRYPTO: SOL), Dogecoin (CRYPTO: DOGE), and more the same way regulators currently treat Bitcoin (CRYPTO: BTC)—as commodities, not securities. How Tokens Get...

Beyond Air Deals Autism-Focused NeuroNOS To XTL For Equity, Future Payments

by Lekha Gupta | Jan 13, 2026 | General

Beyond Air, Inc. (NASDAQ:XAIR) shares are rocketing on Tuesday after the company disclosed a deal with XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) to sell 85% of its subsidiary company, NeuroNOS Ltd. The consideration includes 19.9% of XTL’s issued shares, $1...

SciSparc Moves Into Endoscopy With Strategic Patent Deal

by Nabaparna Bhattacharya | Jan 13, 2026 | General

SciSparc Ltd. (NASDAQ:SPRC) announced a definitive agreement to acquire a portfolio of medical endoscopy patents on Tuesday. • SciSparc shares are retreating from recent levels. What’s behind SPRC decline? The company provided details of its planned purchase of...

Equinor Secures 35 New Norwegian Offshore Licenses

by Nabaparna Bhattacharya | Jan 13, 2026 | General

Equinor ASA (NYSE:EQNR) on Tuesday said it secured fresh acreage in the latest licensing round on Norway’s continental shelf. The company outlined access to new blocks across key offshore regions. Equinor was awarded 35 new production licenses in the Awards in...

Morgan Stanley’s PE Arm Takes Control Of Engineering Firm Olsson

by Nabaparna Bhattacharya | Jan 13, 2026 | General

Morgan Stanley (NYSE:MS) on Tuesday announced that its middle-market private equity arm has struck a majority investment deal with engineering firm Olsson, Inc. Morgan Stanley Capital Partners agreed to take a majority stake in Olsson, a prominent employee-owned...

FDA Says No Clear Link Found Between Popular Weight Loss Drugs And Suicidal Thoughts, Review Ongoing

by Vandana Singh | Jan 13, 2026 | General

The U.S. Food and Drug Administration (FDA) on Tuesday said its preliminary review has not found evidence that glucagon-like peptide-1 receptor agonists, commonly known as GLP-1 RAs, cause suicidal thoughts or actions. Current prescribing information for GLP-1 drugs,...
« Older Entries
Next Entries »

Recent Posts

  • High Roller Technologies, Critical Metals Corp., MongoDB, Citigroup And Rivian: Why These 5 Stocks Are On Investors’ Radars Today
  • Anthony Scaramucci Once Revealed What He Did After Discovering His Dad’s Hours Were Cut During The 1975 Recession: ‘He Needed That Money By Hour…’
  • Copper Will Go ‘Parabolic’: Chamath Predicts A Squeeze
  • Bank Of America Tops Q4 Estimates As AI Drives Account Growth, Reduces Hiring Needs
  • Chipotle Boycotts? Social Media Tries To Hurt Bill Ackman’s Finances After He Donates To ICE Agent

Recent Comments

    Archives

    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • October 2019
    • September 2019
    • August 2019
    • July 2019
    • June 2019

    Categories

    • Breaking
    • Business
    • Daily
    • General
    • Markets
    • News
    • Reports
    • Technology

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • News
    • Privacy Policy
    • Terms of Use
    • Disclaimer
    Copyright 2019 Karmaholic Media LLC. All Rights Reserved.